NRx Cost Of Revenue vs Income Before Tax Analysis

NRXPW Stock

USD 0.05 0 2.00%

NRx Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating NRx Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NRx Pharmaceuticals is a good investment. Please check the relationship between NRx Pharmaceuticals Cost Of Revenue and its Income Before Tax accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NRx Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy NRx Stock please use our How to Invest in NRx Pharmaceuticals guide.

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NRx Pharmaceuticals Cost Of Revenue account and Income Before Tax. At this time, the significance of the direction appears to have strong relationship.

The correlation between NRx Pharmaceuticals' Cost Of Revenue and Income Before Tax is 0.75. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of NRx Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of NRx Pharmaceuticals' Cost Of Revenue and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of NRx Pharmaceuticals are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Cost Of Revenue i.e., NRx Pharmaceuticals' Cost Of Revenue and Income Before Tax go up and down completely randomly.

Correlation Coefficient

0.75

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on NRx Pharmaceuticals income statement and represents the costs associated with goods and services NRx Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on NRx Pharmaceuticals income statement and is an important metric when analyzing NRx Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most indicators from NRx Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NRx Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NRx Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy NRx Stock please use our How to Invest in NRx Pharmaceuticals guide.Selling General Administrative is likely to climb to about 28.2 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 8.9 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	94.4M	44.4M	27.6M	32.9M
Cost Of Revenue	2K	4K	5K	4.8K

Total Operating Expenses Cost Of Revenue

NRx Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Non Current Liabilities Total	Net Tangible Assets	Long Term Debt	Net Receivables	Retained Earnings Total Equity	Capital Surpluse
Total Assets		-0.6	-0.83	0.98	0.08	0.83	-0.88	-0.46	0.96	-0.6	-0.46	0.88	-0.52	0.97	-0.47	-0.79	-0.84	-0.49	0.97	-0.68	0.13	0.58	-0.66	0.7	-0.59	0.58
Other Current Liab	-0.6		0.59	-0.62	0.02	-0.09	0.34	0.0	-0.5	-0.05	0.0	-0.27	0.23	-0.51	-0.03	0.05	0.61	0.01	-0.53	0.0	0.36	0.06	-0.05	0.06	-0.06	0.06
Total Current Liabilities	-0.83	0.59		-0.91	-0.11	-0.6	0.77	0.32	-0.79	0.3	0.32	-0.81	0.59	-0.78	0.32	0.49	1.0	0.34	-0.78	0.37	-0.2	-0.27	0.4	-0.4	0.31	-0.27
Total Stockholder Equity	0.98	-0.62	-0.91		0.09	0.79	-0.87	-0.43	0.94	-0.52	-0.43	0.89	-0.56	0.94	-0.45	-0.72	-0.92	-0.46	0.94	-0.61	0.15	0.51	-0.6	0.63	-0.52	0.51
Net Debt	0.08	0.02	-0.11	0.09		0.27	-0.33	-0.84	0.32	0.28	-0.84	0.36	-0.71	0.31	-0.53	-0.31	-0.11	-0.82	0.31	0.13	0.07	-0.33	-0.44	0.4	0.33	-0.33
Retained Earnings	0.83	-0.09	-0.6	0.79	0.27		-0.88	-0.71	0.9	-0.68	-0.71	0.94	-0.62	0.9	-0.73	-0.99	-0.61	-0.74	0.89	-0.85	0.3	0.66	-0.93	0.96	-0.69	0.66
Accounts Payable	-0.88	0.34	0.77	-0.87	-0.33	-0.88		0.61	-0.91	0.53	0.61	-0.92	0.58	-0.91	0.49	0.83	0.76	0.64	-0.9	0.58	-0.4	-0.47	0.83	-0.8	0.65	-0.47
Cash	-0.46	0.0	0.32	-0.43	-0.84	-0.71	0.61		-0.68	0.14	1.0	-0.71	0.84	-0.67	0.84	0.75	0.32	1.0	-0.67	0.42	-0.1	-0.13	0.8	-0.81	0.07	-0.13
Non Current Assets Total	0.96	-0.5	-0.79	0.94	0.32	0.9	-0.91	-0.68		-0.52	-0.68	0.94	-0.7	1.0	-0.65	-0.87	-0.8	-0.71	1.0	-0.69	0.12	0.5	-0.79	0.82	-0.5	0.5
Non Currrent Assets Other	-0.6	-0.05	0.3	-0.52	0.28	-0.68	0.53	0.14	-0.52		0.14	-0.55	-0.05	-0.52	0.17	0.67	0.29	0.16	-0.51	0.7	-0.47	-0.87	0.55	-0.62	0.87	-0.87
Cash And Short Term Investments	-0.46	0.0	0.32	-0.43	-0.84	-0.71	0.61	1.0	-0.68	0.14		-0.71	0.84	-0.67	0.84	0.75	0.32	1.0	-0.67	0.42	-0.1	-0.13	0.8	-0.81	0.07	-0.13
Common Stock Total Equity	0.88	-0.27	-0.81	0.89	0.36	0.94	-0.92	-0.71	0.94	-0.55	-0.71		-0.73	0.94	-0.68	-0.89	-0.82	-0.74	0.93	-0.69	0.33	0.52	-0.82	0.85	-0.53	0.52
Common Stock Shares Outstanding	-0.52	0.23	0.59	-0.56	-0.71	-0.62	0.58	0.84	-0.7	-0.05	0.84	-0.73		-0.68	0.87	0.6	0.6	0.86	-0.68	0.4	0.16	0.1	0.64	-0.61	-0.1	0.1
Short Term Investments	0.97	-0.51	-0.78	0.94	0.31	0.9	-0.91	-0.67	1.0	-0.52	-0.67	0.94	-0.68		-0.64	-0.87	-0.79	-0.7	1.0	-0.69	0.11	0.5	-0.78	0.81	-0.51	0.5
Other Current Assets	-0.47	-0.03	0.32	-0.45	-0.53	-0.73	0.49	0.84	-0.65	0.17	0.84	-0.68	0.87	-0.64		0.76	0.34	0.86	-0.64	0.7	0.23	-0.15	0.78	-0.79	0.13	-0.15
Other Stockholder Equity	-0.79	0.05	0.49	-0.72	-0.31	-0.99	0.83	0.75	-0.87	0.67	0.75	-0.89	0.6	-0.87	0.76		0.5	0.78	-0.86	0.86	-0.26	-0.67	0.94	-0.99	0.66	-0.67
Total Liab	-0.84	0.61	1.0	-0.92	-0.11	-0.61	0.76	0.32	-0.8	0.29	0.32	-0.82	0.6	-0.79	0.34	0.5		0.35	-0.79	0.39	-0.16	-0.27	0.4	-0.41	0.3	-0.27
Total Current Assets	-0.49	0.01	0.34	-0.46	-0.82	-0.74	0.64	1.0	-0.71	0.16	1.0	-0.74	0.86	-0.7	0.86	0.78	0.35		-0.7	0.46	-0.09	-0.15	0.82	-0.83	0.1	-0.15
Common Stock	0.97	-0.53	-0.78	0.94	0.31	0.89	-0.9	-0.67	1.0	-0.51	-0.67	0.93	-0.68	1.0	-0.64	-0.86	-0.79	-0.7		-0.68	0.1	0.49	-0.78	0.81	-0.5	0.49
Short Long Term Debt Total	-0.68	0.0	0.37	-0.61	0.13	-0.85	0.58	0.42	-0.69	0.7	0.42	-0.69	0.4	-0.69	0.7	0.86	0.39	0.46	-0.68		0.02	-0.7	0.76	-0.81	0.7	-0.7
Non Current Liabilities Total	0.13	0.36	-0.2	0.15	0.07	0.3	-0.4	-0.1	0.12	-0.47	-0.1	0.33	0.16	0.11	0.23	-0.26	-0.16	-0.09	0.1	0.02		0.48	-0.23	0.28	-0.49	0.48
Net Tangible Assets	0.58	0.06	-0.27	0.51	-0.33	0.66	-0.47	-0.13	0.5	-0.87	-0.13	0.52	0.1	0.5	-0.15	-0.67	-0.27	-0.15	0.49	-0.7	0.48		-0.45	0.61	-0.8	1.0
Long Term Debt	-0.66	-0.05	0.4	-0.6	-0.44	-0.93	0.83	0.8	-0.79	0.55	0.8	-0.82	0.64	-0.78	0.78	0.94	0.4	0.82	-0.78	0.76	-0.23	-0.45		-0.96	0.62	-0.45
Net Receivables	0.7	0.06	-0.4	0.63	0.4	0.96	-0.8	-0.81	0.82	-0.62	-0.81	0.85	-0.61	0.81	-0.79	-0.99	-0.41	-0.83	0.81	-0.81	0.28	0.61	-0.96		-0.62	0.61
Retained Earnings Total Equity	-0.59	-0.06	0.31	-0.52	0.33	-0.69	0.65	0.07	-0.5	0.87	0.07	-0.53	-0.1	-0.51	0.13	0.66	0.3	0.1	-0.5	0.7	-0.49	-0.8	0.62	-0.62		-0.8
Capital Surpluse	0.58	0.06	-0.27	0.51	-0.33	0.66	-0.47	-0.13	0.5	-0.87	-0.13	0.52	0.1	0.5	-0.15	-0.67	-0.27	-0.15	0.49	-0.7	0.48	1.0	-0.45	0.61	-0.8

Click cells to compare fundamentals

NRx Pharmaceuticals Account Relationship Matchups

NRx Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	32.1M	2.9M	32.7M	25.8M	7.3M	6.9M
Total Current Liabilities	622.4K	46.2M	11.9M	16.6M	19.0M	14.9M
Total Stockholder Equity	29.5M	(43.8M)	20.8M	7.4M	(11.7M)	(11.1M)
Net Debt	2.0M	(1.1M)	(27.1M)	(9.5M)	4.6M	4.8M
Retained Earnings	369.5K	(90.2M)	(183.2M)	(223.1M)	(253.1M)	(240.5M)
Accounts Payable	622.4K	3.2M	3.7M	2.1M	4.6M	2.3M
Cash	6.0	1.9M	27.6M	20.1M	4.6M	8.6M
Non Current Assets Total	32.0M	11K	15K	21K	431K	409.5K
Non Currrent Assets Other	1.0	11K	15K	21K	431K	452.6K
Cash And Short Term Investments	6.0	1.9M	27.6M	20.1M	4.6M	8.6M
Common Stock Shares Outstanding	508.8K	34.3M	46.9M	65.8M	7.6M	7.2M
Liabilities And Stockholders Equity	32.1M	2.9M	32.7M	25.8M	7.3M	6.9M
Other Current Assets	69.5K	240K	5.1M	11.5M	2.3M	3.0M
Other Stockholder Equity	29.1M	46.4M	204.0M	230.3M	241.3M	253.4M
Total Liab	2.6M	46.7M	11.9M	18.4M	19.0M	15.7M
Total Current Assets	69.5K	2.9M	32.7M	25.8M	6.9M	10.8M
Common Stock	24.5M	43K	59K	67K	84K	79.8K
Short Long Term Debt Total	2.0M	797K	518K	10.5M	9.2M	9.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for NRx Stock Analysis

When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NRx Cost Of Revenue vs Income Before Tax Analysis

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Income Before Tax

NRx Pharmaceuticals fundamental ratios Correlations

NRx Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NRx Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for NRx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Short Term Investments	+ 1.0	Non Current Assets Total
Common Stock	+ 1.0	Non Current Assets Total
Total Current Assets	+ 1.0	Cash And Short Term Investments

Net Receivables	- 0.99	Other Stockholder Equity
Other Stockholder Equity	- 0.99	Retained Earnings
Net Receivables	- 0.96	Long Term Debt
Long Term Debt	- 0.93	Retained Earnings
Common Stock Total Equity	- 0.92	Accounts Payable
Total Liab	- 0.92	Total Stockholder Equity